Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01562873 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib in Patients With Breast Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT01562873 is a Phase 2 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 21 participants.
The verdict
NCT01562873, a Phase 2 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
Ruxolitinib is a drug which blocks the Janus tyrosine Kinase (JAK) signaling pathway. It is thought that this pathway might be important in certain types of breast cancer, and that blocking this pathway might lead to anti-cancer effects. This study is testing the effects of ruxolitinib in patients with breast cancer.
Interventions
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-06 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01562873
The ClinicalTrials.gov registry entry for NCT01562873 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT01562873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01562873 about?
NCT01562873 is a clinical study titled "Ruxolitinib in Patients With Breast Cancer". Ruxolitinib is a drug which blocks the Janus tyrosine Kinase (JAK) signaling pathway. It is thought that this pathway might be important in certain types of breast cancer, and that blocking this pathway might lead to anti-cancer effects. This study is testing the effects of ruxolitinib in patients w...
What is the current status of trial NCT01562873?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2012-06. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01562873?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT01562873?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.